Last reviewed · How we verify
Calciumfolinat
Calciumfolinat is a Small molecule drug developed by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest. It is currently in Phase 2 development. Also known as: Leucovorin.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Calciumfolinat |
|---|---|
| Also known as | Leucovorin |
| Sponsor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness (PHASE2)
- HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT) (PHASE3)
- FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) (PHASE2, PHASE3)
- PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer (NA)
- Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt- (NA)
- Tailored Treatment in Metastatic Colorectal Cancer (PHASE3)
- A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calciumfolinat CI brief — competitive landscape report
- Calciumfolinat updates RSS · CI watch RSS
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest portfolio CI
Frequently asked questions about Calciumfolinat
What is Calciumfolinat?
Who makes Calciumfolinat?
Is Calciumfolinat also known as anything else?
What development phase is Calciumfolinat in?
Related
- Manufacturer: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Leucovorin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing